• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Williams Gregg bought $24,959 worth of shares (24,939 units at $1.00), increasing direct ownership by 0.53% to 4,720,800 units (SEC Form 4)

    4/4/25 8:21:50 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VANI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Williams Gregg

    (Last) (First) (Middle)
    C/O 1350 S. LOOP ROAD

    (Street)
    ALAMEDA CA 94502

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vivani Medical, Inc. [ VANI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/02/2025 P(1) 2,000 A $1.01 4,697,861 D
    Common Stock 04/03/2025 P(1) 22,939 A $1 4,720,800 D
    Common Stock 13,677,308 I See footnote(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the open market. The reporting person undertakes to provide to Vivani Medical, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in each transaction set forth in this footnote.
    2. In addition to the shares the reporting person purchased directly in his name on the open market and in the private sale transaction, the reporting person owns 13,677,308 shares indirectly as follows: (i) 11,551,556 shares of common stock owned by Gregg G. Williams 2006 Trust, (ii) 1,212,856 shares of common stock owned by Williams International Co. LLC, (iii) 181,587 shares of common stock owned by Sam Williams Family Investments LLC, and (iv) 731,309 shares of common stock owned by Sam B. Williams 1995 Generation-Skipping Trust. Gregg Williams has voting and dispositive power over all of these shares.
    /s/ Brigid Makes as Attorney-in-fact 04/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VANI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VANI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VANI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vivani Medical Appoints Anthony Baldor as Chief Financial Officer

      ALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid A. Makes, who has decided to retire from Vivani to focus on her board appointments and personal projects after a distinguished career and significant contributions to the Company. Baldor brings more than 20 years of financial management experience in the biotechnology sector, with a proven record in fundraising, business development and corporate strategy. Prior to joining Vivani,

      6/11/25 8:00:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical to Present at the 2025 BIO International Convention

      ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the 2025 BIO International Convention, taking place from June 16-19, 2025 in Boston, Massachusetts. Details around Dr. Mendelsohn's presentation are as follows: Date:Wednesday, June 18, 2025Time:9:00 am, Eastern TimeLocation: Boston Convention & Exhibition Center, Room 153A   Dr. Mendelsohn will highlight Vivani's innovative, miniature drug implants, powered by its

      6/10/25 8:30:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders

      Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion® Visual Cortical Prosthesis System to provide meaningful visual perception to people who are blind Cortigent is developing the Stroke Recovery System to improve the recovery of arm and hand movement in people who have suffered paralysis due to stroke Spin-off will allow Vivani to focus on its continued development of miniature, ultra long-acting GLP-1 implants for chronic weight management and type 2 diabetes with annual or bi-annual dosing ALAMEDA, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Viv

      5/29/25 8:30:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Williams Gregg bought $12,867 worth of shares (12,740 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/16/25 8:11:15 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Business Officer Dwyer Donald

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/14/25 8:38:41 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Makes Brigid

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/14/25 8:31:54 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    SEC Filings

    See more
    • Vivani Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      6/11/25 8:45:22 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      5/29/25 8:45:30 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Vivani Medical Inc.

      10-Q - Vivani Medical, Inc. (0001266806) (Filer)

      5/13/25 4:47:30 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

      SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

      5/1/23 8:42:07 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by Vivani Medical Inc.

      SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

      4/25/23 5:28:48 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Williams Gregg bought $12,867 worth of shares (12,740 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/16/25 8:11:15 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Williams Gregg bought $1,124 worth of shares (1,113 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      4/28/25 7:59:38 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Williams Gregg bought $1,830 worth of shares (1,812 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      4/23/25 8:41:13 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care